Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Jordan L. Lacoste"'
Autor:
Muchi Ditah Chobufo, Sean R Regner, Irfan Zeb, Jordan L Lacoste, Salim S Virani, Sudarshan Balla
Publikováno v:
European Journal of Preventive Cardiology. 29:1830-1838
Aims To assess the current state of statin use, factors associated with non-use, and estimate the burden of potentially preventable atherosclerotic cardiovascular diseases (ASCVD) events. Methods and results Using nationally representative data from
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a0698761a954307f978a5ded7b3a785
https://doi.org/10.1093/eurjpc/zwac103
https://doi.org/10.1093/eurjpc/zwac103
Autor:
Jordan L. Lacoste, Thomas W. Szymanski, Juan Carlo Avalon, Galen Kabulski, Utkarsh Kohli, Nassir Marrouche, Atul Singla, Sudarshan Balla, Arshad Jahangir
Publikováno v:
American Journal of Cardiovascular Drugs. 22:475-496
Atrial fibrillation (AF) is an increasingly common arrhythmia encountered in clinical practice that leads to a substantial increase in utilization of healthcare services and a decrease in the quality of life of patients. The prevalence of AF will con
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4fe8f4c46c21be543eb974e21e220330
https://doi.org/10.1007/s40256-022-00529-6
https://doi.org/10.1007/s40256-022-00529-6
Autor:
Juan Carlo Avalon, Wei Fang, Laura Davisson, Cavan P. O’Kane, Kara Piechowski, Christopher Bianco, Jordan L. Lacoste
Publikováno v:
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 42:112-118
BACKGROUND Apixaban and rivaroxaban are increasingly used for thromboembolism prophylaxis in patients with nonvalvular atrial fibrillation (NVAF) and commonly in patients with obesity and body mass index (BMI) ≥50 kg/m2 despite limited data. OBJECT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0992ff5e37c7a5eb053eea4621d125ef
https://doi.org/10.1002/phar.2651
https://doi.org/10.1002/phar.2651
Autor:
Cavan P, O'Kane, Juan Carlo O, Avalon, Jordan L, Lacoste, Wei, Fang, Christopher M, Bianco, Laura, Davisson, Kara L, Piechowski
Publikováno v:
PharmacotherapyREFERENCES. 42(2)
Apixaban and rivaroxaban are increasingly used for thromboembolism prophylaxis in patients with non-valvular atrial fibrillation (NVAF) and commonly in patients with obesity and body mass index (BMI) ≥50 kg/mThis study aimed to establish the effect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::00718bb66456d34bf3376c67311914be
https://pubmed.ncbi.nlm.nih.gov/34820876
https://pubmed.ncbi.nlm.nih.gov/34820876
Autor:
Cory L Hansen, Jordan L Lacoste
Publikováno v:
American Journal of Health-System Pharmacy. 76:1395-1402
Purpose Updates to the primary literature and clinical practice guidelines on use of antithrombotic combinations for patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) and stenting are reviewed. Summary Up to 8
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca9e675a45cb87050f2663f14cd5bec3
https://doi.org/10.1093/ajhp/zxz152
https://doi.org/10.1093/ajhp/zxz152